Shares of Scholar Rock Holding Corporation (SRRK) are rising more than 15% Wednesday morning, continuing the momentum from yesterday.
Tuesday, the company announced positive interim results from the phase II study of its drug candidate SRK-015 for the treatment of patients with type 2 and type 3 spinal muscular atrophy (SMA).
The stock hit a new high of $36.40 this morning by jumping nearly 100% from the opening price of $17.25, recorded Tuesday.
For comments and feedback contact: editorial@rttnews.com
